文献速递肿瘤 PET/CT放射性药物与辐射防护

68Ga-DOTATATE比较剂量学:采用更新ICRP体模、S值与组织权重因子的影响

Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors.
PubMed 文献 · J Nucl Med · 2018-02-09

本研究对16例患者行68Ga-DOTATATE全身PET/CT,分别用CE体模+ICRP 60组织权重因子与ICRP 110体模+ICRP 103组织权重因子计算有效剂量。ICRP 110+ICRP 103的有效剂量系数为0.023±0.003 mSv/MBq,显著低于CE+ICRP 60的0.027±0.005 mSv/MBq。结论为CE体模略高估有效剂量系数。

要点

  • ICRP 110体模+ICRP 103组织权重因子的有效剂量系数为0.023±0.003 mSv/MBq。
  • CE体模+ICRP 60组织权重因子的有效剂量系数为0.027±0.005 mSv/MBq,高于前者。
  • 膀胱壁吸收剂量系数在ICRP 110体模为0.040±0.011 mGy/MBq,CE体模为0.090±0.032 mGy/MBq。

核心结论

  • 本研究表明,与采用ICRP 103最新组织权重因子的ICRP 110体模相比,CE体模的有效剂量系数被轻度高估。

研究设计与样本

  • 对16例患者给予68Ga-DOTATATE后行全身PET/CT扫描,在CT图像上勾画脾、肝、肾、肾上腺、脑、心、肺、甲状腺、唾液腺、睾丸、红骨髓(L1-L5)、肌肉(右大腿)及全身。
  • 剂量学计算基于CE体模与ICRP 110参考体素体模,CE体模采用ICRP 60组织权重因子,ICRP 110体模采用ICRP 103组织权重因子。

主要发现

  • 吸收剂量系数(单位活度吸收剂量)由高到低依次为脾、垂体、肾、肾上腺、肝。
  • ICRP 110体模+ICRP 103组织权重因子的有效剂量系数为0.023±0.003 mSv/MBq,显著低于CE体模+ICRP 60组织权重因子的0.027±0.005 mSv/MBq。
  • 估计吸收剂量系数差异最大的部位之一是膀胱壁,ICRP 110体模为0.040±0.011 mGy/MBq,CE体模为0.090±0.032 mGy/MBq。
  • 最新体模计算对电子输运处理更细致,使消化道管壁器官干细胞吸收剂量估计出现显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The data that have been used in almost all calculations of MIRD S value absorbed dose and effective dose are based on stylized anatomic computational phantoms and tissue-weighting factors adopted by the International Commission on Radiological Protection (ICRP) in its publication 60. The more anatomically realistic phantoms that have recently become available are likely to provide more accurate effective doses for diagnostic agents. 68Ga-DOTATATE is a radiolabeled somatostatin analog that binds with high affinity to somatostatin receptors, which are overexpressed in neuroendocrine tumors and can be used for diagnostic PET/CT-based imaging. Several studies have reported effective doses for 68Ga-DOTATATE using the stylized Cristy-Eckerman (CE) phantoms from 1987; here, we present effective dose calculations using both the ICRP 60 and more updated formalisms. Methods: Whole-body PET/CT scans were acquired for 16 patients after 68Ga-DOTATATE administration. Contours were drawn on the CT images for spleen, liver, kidneys, adrenal glands, brain, heart, lungs, thyroid gland, salivary glands, testes, red marrow (L1-L5), muscle (right thigh), and whole body. Dosimetric calculations were based on the CE phantoms and the more recent ICRP 110 reference-voxel phantoms. Tissue-weighting factors from ICRP 60 and ICRP 103 were used in effective dose calculations for the CE phantoms and ICRP 110 phantoms, respectively. Results: The highest absorbed dose coefficients (absorbed dose per unit activity) were, in descending order, in the spleen, pituitary gland, kidneys, adrenal glands, and liver. For ICRP 110 phantoms with tissue-weighting factors from ICRP 103, the effective dose coefficient was 0.023 ± 0.003 mSv/MBq, which was significantly lower than the 0.027 ± 0.005 mSv/MBq calculated for CE phantoms with tissue-weighting factors from ICRP 60. One of the largest differences in estimated absorbed dose coefficients was for the urinary bladder wall, at 0.040 ± 0.011 mGy/MBq for ICRP 110 phantoms compared with 0.090 ± 0.032 mGy/MBq for CE phantoms. Conclusion: This study showed that the effective dose coefficient was slightly overestimated for CE phantoms, compared with ICRP 110 phantoms using the latest tissue-weighting factors from ICRP 103. The more detailed handling of electron transport in the latest phantom calculations gives significant differences in estimates of the absorbed dose to stem cells in the walled organs of the alimentary tract.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Josefsson A, Hobbs RF, Ranka S, et al. Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors. J Nucl Med. 2018. PMID: 29439017. doi:10.2967/jnumed.117.203893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。